Engineering Coumarin‐Based Afterglow Luminescence Probes for Activatable Imaging Peroxynitrite In Vivo
Abstract
ABSTRACT Afterglow luminescence imaging materials have evolved from inorganic to organic systems, and further from macromolecular polymers to small molecules, highlighting the imperative of developing safe and efficient organic afterglow molecules for bioimaging. However, flexible organic afterglow molecules with well‐characterized structure–luminescence intensity relationships for high‐contrast activatable imaging remain scarce. Here, we report for the first time that coumarin derivatives exhibit bright afterglow luminescence and reveal that rigidified coumarin structures display stronger emission than their flexible and backbone analogues. Further, we designed MP molecules bearing boronic ester and methylenecyclobutane moieties and integrated them with coumarin to construct the activatable afterglow probe C545–MP NPs. Oxidation of the boronic ester by ONOO − primes the probe, whereas subsequent irradiation induces coumarin‐mediated singlet oxygen generation that reacts with the methylenecyclobutane unit to initiate afterglow emission. By virtue of the elimination of autofluorescence and high activation contrast, C545–MP NPs enable precise assessing therapeutic efficacy of ulcerative colitis and Parkinson′s disease.
Article Details
Authors (9)
Youjuan Wang
Department of Diagnostic Ultrasound Imaging & Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou Institute of Medicine (HIM)
Yun Zhang
Pengge Zhang
Department of Clinical Laboratory, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Protein Detection Technology and Diagnostic Equipment, The Key Laboratory of Zhejiang Province For Aptamers and Theranostics Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou 310022 China
Hongzhen Wang
Yanfen Xu
Dong Xu
Department of Diagnostic Ultrasound Imaging & Interventional Therapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou Institute of Medicine (HIM)
Ting Fu
Xue‐Qiang Wang
Department of Clinical Laboratory, Zhejiang Cancer Hospital, Zhejiang Provincial Key Laboratory of Protein Detection Technology and Diagnostic Equipment, The Key Laboratory of Zhejiang Province For Aptamers and Theranostics Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences Hangzhou 310022 China
Weihong Tan
Institute of Molecular Medicine (IMM), Department of Nephrology, Molecular Cell Laboratory for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Uremia Diagnosis and Treatment Center, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital, School of Medicine, School of Chemistry and Chemical Engineering